Invesco Ltd. lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 91.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,084,753 shares of the company's stock after purchasing an additional 519,186 shares during the period. Invesco Ltd. owned about 3.49% of Medpace worth $360,387,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. R Squared Ltd purchased a new stake in Medpace in the 4th quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new position in shares of Medpace during the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp lifted its stake in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. Finally, Assetmark Inc. grew its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Price Performance
Shares of NASDAQ:MEDP traded down $2.21 during trading on Tuesday, reaching $303.07. 185,354 shares of the company were exchanged, compared to its average volume of 320,112. The firm has a market capitalization of $9.16 billion, a PE ratio of 24.00, a P/E/G ratio of 3.81 and a beta of 1.46. The business's fifty day simple moving average is $322.58 and its 200-day simple moving average is $334.29. Medpace Holdings, Inc. has a 12-month low of $272.00 and a 12-month high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.
Analyst Ratings Changes
MEDP has been the topic of several research reports. Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and dropped their target price for the stock from $370.00 to $328.00 in a report on Monday. Mizuho dropped their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a research note on Monday, March 24th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average price target of $357.50.
Check Out Our Latest Stock Report on MEDP
Medpace Company Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Further Reading
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
